Dana Zakalik, MD
Hematology & Oncology · Royal Oak, MINPI 1033179973
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in MI, where the typical reported total is $1,604.
Across 30 payments — averaging $44.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$237
- Caris MPI, Inc.$168
- Genentech USA, Inc.$119
- Lilly USA, LLC$114
- Tempus AI, Inc$113
- Hologic Sales And Service, LLC$81
- plus $513 from 15 others
Across 11 payments — averaging $1707.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$19K
What the payments were for
- Food & beverage$1,32599%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $237 |
| Caris MPI, Inc. | 1 | $168 |
| Genentech USA, Inc. | 2 | $119 |
| Lilly USA, LLC | 1 | $114 |
| Tempus AI, Inc | 1 | $113 |
| Hologic Sales And Service, LLC | 1 | $81 |
| Novartis | 4 | $77 |
| Promega Corporation | 1 | $59 |
| Sanofi | 2 | $57 |
| Genmab U.S., Inc. | 2 | $47 |
| Johnson & Johnson(2 entities) | 2 | $43 |
| Bristol Myers Squibb | 2 | $34 |
| Amgen | 1 | $32 |
| Merck | 1 | $25 |
| Bayer | 1 | $24 |
| Mirati Therapeutics, Inc. | 1 | $23 |
| Sun Pharmaceutical Industries Inc. | 1 | $21 |
| AVEO Pharmaceuticals, Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$237
- MI CANCER SEEK$168
- Kadcyla$105
How this compares
$1,345 in reported general payments places this provider in the 45th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Royal Oak
- Samer BallouzRoyal Oak$29K
- Matthew CotantRoyal Oak$17K
- Elisa QuirozRoyal Oak$13K
- Laura NadeauRoyal Oak$11K
- Martin TapiaRoyal Oak$10K
- Deepa JagtapRoyal Oak$9K
- Ishmael JaiyesimiRoyal Oak$9K
- Faisal MusaDearborn$976K
- Mohammed Al HallakDetroit$644K
- Daniel LebovicGrosse Pointe Woods$352K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.